Cargando…
Nanoparticles in clinical trials of COVID-19: An update
Once the World Health Organization (WHO) declared the COVID-19 (Coronavirus Infectious Disease-19) outbreak to be pandemic, massive efforts have been launched by researchers around the globe to combat this emerging infectious disease. Strategies that must be investigated such as expanding testing ca...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
IJS Publishing Group Ltd. Published by Elsevier Ltd.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9359769/ https://www.ncbi.nlm.nih.gov/pubmed/35953020 http://dx.doi.org/10.1016/j.ijsu.2022.106818 |
_version_ | 1784764204616515584 |
---|---|
author | Rauf, Abdur Abu-Izneid, Tareq Khalil, Anees Ahmed Hafeez, Nabia Olatunde, Ahmed Rahman, Md. Mominur Semwal, Prabhakar Al-Awthan, Yahya Saleh Bahattab, Omar Salem Khan, Ishaq N. Khan, Muhammad Arslan Sharma, Rohit |
author_facet | Rauf, Abdur Abu-Izneid, Tareq Khalil, Anees Ahmed Hafeez, Nabia Olatunde, Ahmed Rahman, Md. Mominur Semwal, Prabhakar Al-Awthan, Yahya Saleh Bahattab, Omar Salem Khan, Ishaq N. Khan, Muhammad Arslan Sharma, Rohit |
author_sort | Rauf, Abdur |
collection | PubMed |
description | Once the World Health Organization (WHO) declared the COVID-19 (Coronavirus Infectious Disease-19) outbreak to be pandemic, massive efforts have been launched by researchers around the globe to combat this emerging infectious disease. Strategies that must be investigated such as expanding testing capabilities, developing effective medicines, as well as developing safe and effective vaccines for COVID-19 disease that produce long-lasting immunity to human system. Now-a-days, bio-sensing, medication delivery, imaging, and antimicrobial treatment are just a few of the medical applications for nanoparticles (NPs). Since the early 1990s, nanoparticle drug delivery methods have been employed in clinical trials. Since then, the discipline of nanomedicine has evolved in tandem with expanding technological demands to better medicinal delivery. Newer generations of NPs have emerged in recent decades that are capable of performing additional delivery tasks, allowing for therapy via novel therapeutic modalities. Many of these next generation NPs and associated products have entered clinical trials and have been approved for diverse indications in the present clinical environment. For systemic applications, NPs or nanomedicine-based drug delivery systems have substantial benefits over their non-formulated and free drug counterparts. Nanoparticle systems, for example, are capable of delivering medicines and treating parts of the body that are inaccessible to existing delivery systems. As a result, NPs medication delivery is one of the most studied preclinical and clinical systems. NPs-based vaccines delivering SARS-CoV-2 antigens will play an increasingly important role in prolonging or improving COVID-19 vaccination outcomes. This review provides insights about employing NPs-based drug delivery systems for the treatment of COVID-19 to increase the bioavailability of current drugs, reducing their toxicity, and to increase their efficiency. This article also exhibits their capability and efficacy, and highlighting the future aspects and challenges on nanoparticle products in clinical trials of COVID-19. |
format | Online Article Text |
id | pubmed-9359769 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | IJS Publishing Group Ltd. Published by Elsevier Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-93597692022-08-09 Nanoparticles in clinical trials of COVID-19: An update Rauf, Abdur Abu-Izneid, Tareq Khalil, Anees Ahmed Hafeez, Nabia Olatunde, Ahmed Rahman, Md. Mominur Semwal, Prabhakar Al-Awthan, Yahya Saleh Bahattab, Omar Salem Khan, Ishaq N. Khan, Muhammad Arslan Sharma, Rohit Int J Surg Review Once the World Health Organization (WHO) declared the COVID-19 (Coronavirus Infectious Disease-19) outbreak to be pandemic, massive efforts have been launched by researchers around the globe to combat this emerging infectious disease. Strategies that must be investigated such as expanding testing capabilities, developing effective medicines, as well as developing safe and effective vaccines for COVID-19 disease that produce long-lasting immunity to human system. Now-a-days, bio-sensing, medication delivery, imaging, and antimicrobial treatment are just a few of the medical applications for nanoparticles (NPs). Since the early 1990s, nanoparticle drug delivery methods have been employed in clinical trials. Since then, the discipline of nanomedicine has evolved in tandem with expanding technological demands to better medicinal delivery. Newer generations of NPs have emerged in recent decades that are capable of performing additional delivery tasks, allowing for therapy via novel therapeutic modalities. Many of these next generation NPs and associated products have entered clinical trials and have been approved for diverse indications in the present clinical environment. For systemic applications, NPs or nanomedicine-based drug delivery systems have substantial benefits over their non-formulated and free drug counterparts. Nanoparticle systems, for example, are capable of delivering medicines and treating parts of the body that are inaccessible to existing delivery systems. As a result, NPs medication delivery is one of the most studied preclinical and clinical systems. NPs-based vaccines delivering SARS-CoV-2 antigens will play an increasingly important role in prolonging or improving COVID-19 vaccination outcomes. This review provides insights about employing NPs-based drug delivery systems for the treatment of COVID-19 to increase the bioavailability of current drugs, reducing their toxicity, and to increase their efficiency. This article also exhibits their capability and efficacy, and highlighting the future aspects and challenges on nanoparticle products in clinical trials of COVID-19. IJS Publishing Group Ltd. Published by Elsevier Ltd. 2022-08 2022-08-08 /pmc/articles/PMC9359769/ /pubmed/35953020 http://dx.doi.org/10.1016/j.ijsu.2022.106818 Text en © 2022 IJS Publishing Group Ltd. Published by Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Review Rauf, Abdur Abu-Izneid, Tareq Khalil, Anees Ahmed Hafeez, Nabia Olatunde, Ahmed Rahman, Md. Mominur Semwal, Prabhakar Al-Awthan, Yahya Saleh Bahattab, Omar Salem Khan, Ishaq N. Khan, Muhammad Arslan Sharma, Rohit Nanoparticles in clinical trials of COVID-19: An update |
title | Nanoparticles in clinical trials of COVID-19: An update |
title_full | Nanoparticles in clinical trials of COVID-19: An update |
title_fullStr | Nanoparticles in clinical trials of COVID-19: An update |
title_full_unstemmed | Nanoparticles in clinical trials of COVID-19: An update |
title_short | Nanoparticles in clinical trials of COVID-19: An update |
title_sort | nanoparticles in clinical trials of covid-19: an update |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9359769/ https://www.ncbi.nlm.nih.gov/pubmed/35953020 http://dx.doi.org/10.1016/j.ijsu.2022.106818 |
work_keys_str_mv | AT raufabdur nanoparticlesinclinicaltrialsofcovid19anupdate AT abuizneidtareq nanoparticlesinclinicaltrialsofcovid19anupdate AT khalilaneesahmed nanoparticlesinclinicaltrialsofcovid19anupdate AT hafeeznabia nanoparticlesinclinicaltrialsofcovid19anupdate AT olatundeahmed nanoparticlesinclinicaltrialsofcovid19anupdate AT rahmanmdmominur nanoparticlesinclinicaltrialsofcovid19anupdate AT semwalprabhakar nanoparticlesinclinicaltrialsofcovid19anupdate AT alawthanyahyasaleh nanoparticlesinclinicaltrialsofcovid19anupdate AT bahattabomarsalem nanoparticlesinclinicaltrialsofcovid19anupdate AT khanishaqn nanoparticlesinclinicaltrialsofcovid19anupdate AT khanmuhammadarslan nanoparticlesinclinicaltrialsofcovid19anupdate AT sharmarohit nanoparticlesinclinicaltrialsofcovid19anupdate |